Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Dose-dense paclitaxel (Genexol®-PM) once a week in combination with carboplatin every 3 weeks
for gynecologic cancer (adult solid tumor): a phase I trial.